Pfizer Inc. $PFE Shares Sold by International Assets Investment Management LLC

International Assets Investment Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 4.6% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 224,260 shares of the biopharmaceutical company’s stock after selling 10,861 shares during the period. International Assets Investment Management LLC’s holdings in Pfizer were worth $5,227,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter valued at about $27,000. North Capital Inc. bought a new stake in Pfizer in the first quarter valued at about $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter valued at about $28,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer during the second quarter valued at approximately $29,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer during the first quarter valued at approximately $35,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on PFE shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley lowered their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.52 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a 50 day simple moving average of $24.89 and a 200-day simple moving average of $24.11. The company has a market cap of $139.38 billion, a PE ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.36.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.